BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
How Pfizer is trying to make U.S. healthcare easier to navigate
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
FierceBiotech2d
Pfizer plucks internal candidate to replace R&D head Dolsten, triggering series of leadership shakeups
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
FierceBiotech3d
Pfizer, Flagship return to obesity as part of latest additions to multibillion-dollar collaboration
No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Lilly and Pfizer stocks have sold off sharply in recent weeks. Both drugmakers have had some bad news that caused their ...
Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...
Meta, Pfizer on DOL List of Upcoming Contractor Anti-Bias Audits
Meta Platforms Inc, Pfizer Inc and American Airlines are among the companies the Labor Department’s contractor watchdog has ...
FiercePharma1d
As other Big Pharmas face local headwinds, Pfizer doubles down on China commitment with Zai Lab antimicrobial marketing pact
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...